These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
402 related items for PubMed ID: 23713721
1. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities. Healy JR, Bezawada P, Shim J, Jones JW, Kane MA, MacKerell AD, Coop A, Matsumoto RR. ACS Chem Neurosci; 2013 Sep 18; 4(9):1256-66. PubMed ID: 23713721 [Abstract] [Full Text] [Related]
2. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. Wells JL, Bartlett JL, Ananthan S, Bilsky EJ. J Pharmacol Exp Ther; 2001 May 18; 297(2):597-605. PubMed ID: 11303048 [Abstract] [Full Text] [Related]
3. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors. Xu H, Lu YF, Rice KC, Ananthan S, Rothman RB. Brain Res Bull; 2001 Jul 01; 55(4):507-11. PubMed ID: 11543951 [Abstract] [Full Text] [Related]
7. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. Ananthan S, Johnson CA, Carter RL, Clayton SD, Rice KC, Xu H, Davis P, Porreca F, Rothman RB. J Med Chem; 1998 Jul 16; 41(15):2872-81. PubMed ID: 9667975 [Abstract] [Full Text] [Related]
8. Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist. Wang YH, Chai JR, Xu XJ, Ye RF, Zan GY, Liu GY, Long JD, Ma Y, Huang X, Xiao ZC, Dong H, Wang YJ. Sci Rep; 2018 Sep 20; 8(1):14087. PubMed ID: 30237513 [Abstract] [Full Text] [Related]
10. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior. Wang YJ, Tao YM, Li FY, Wang YH, Xu XJ, Chen J, Cao YL, Chi ZQ, Neumeyer JL, Zhang A, Liu JG. J Pharmacol Exp Ther; 2009 Apr 20; 329(1):306-13. PubMed ID: 19136637 [Abstract] [Full Text] [Related]
18. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration. Anand JP, Kochan KE, Nastase AF, Montgomery D, Griggs NW, Traynor JR, Mosberg HI, Jutkiewicz EM. Br J Pharmacol; 2018 Jun 18; 175(11):2013-2027. PubMed ID: 29352503 [Abstract] [Full Text] [Related]
19. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Beattie DT, Cheruvu M, Mai N, O'Keefe M, Johnson-Rabidoux S, Peterson C, Kaufman E, Vickery R. Naunyn Schmiedebergs Arch Pharmacol; 2007 May 18; 375(3):205-20. PubMed ID: 17340127 [Abstract] [Full Text] [Related]